{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:00:18Z","timestamp":1777982418551,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MSD China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cytomegalovirus (CMV) reactivation following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a challenging problem, and the impact on the risk of overall mortality (OM) and non-relapse mortality (NRM) in patients following allo-HSCT is still controversial. Utilizing the evidence mapping method, we aimed to assess the effect of CMV infection on outcomes of patients post-transplantation and identify research gaps through systematic reviews (SRs) and clinical studies. PubMed, EMBASE, Web of Science, and Cochrane library databases were searched from inception until 5 July 2022 to identify relevant literature. After systematic literature screening and data extraction, evidence mapping of the effects of CMV reactivation on patients post-allo-HSCT was conducted. Three SRs and 22 clinical studies were included. In one SR, CMV reactivation was associated with an increased risk of mortality (HR 1.46; 95% CI, 1.24\u20131.72; <jats:italic>P<\/jats:italic>\u2009\u2264\u20090.001). In two SRs, CMV reactivation was associated with NRM. One SR reported CMV reactivation was potentially associated with significant protection against relapse in patients with acute myelocytic leukemia (AML), but no significant correlation with graft-versus-host disease (GVHD) was found. Lastly, in one SR CMV reactivation significantly increased the risk of invasive fungal disease (IFD). Most clinical articles reported that CMV reactivation increased the risk of renal dysfunction, poor graft function, re-hospitalization, and bacterial infections. CMV reactivation following allo-HSCT is associated with an increased risk of OM, NRM, IFD, and renal dysfunction, as well as a reduced risk of relapse in patients with AML.<\/jats:p>","DOI":"10.1007\/s00277-023-05509-7","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T10:02:32Z","timestamp":1705399352000},"page":"917-933","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping"],"prefix":"10.1007","volume":"103","author":[{"given":"Xiaojin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiemei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"issue":"8","key":"5509_CR1","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","volume":"19","author":"P Ljungman","year":"2019","unstructured":"Ljungman P et al (2019) Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 19(8):e260\u2013e272","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"5509_CR2","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","volume":"3","author":"ML Green","year":"2016","unstructured":"Green ML et al (2016) Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol 3(3):e119\u2013e127","journal-title":"Lancet Haematol"},{"issue":"20","key":"5509_CR3","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","volume":"127","author":"P Teira","year":"2016","unstructured":"Teira P et al (2016) Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood 127(20):2427\u20132438","journal-title":"Blood"},{"issue":"4","key":"5509_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00277-011-1351-8","volume":"91","author":"YC Liu","year":"2012","unstructured":"Liu YC et al (2012) Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus. Ann Hematol 91(4):587\u2013595","journal-title":"Ann Hematol"},{"issue":"6","key":"5509_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/QCO.0000000000000502","volume":"31","author":"MK Yong","year":"2018","unstructured":"Yong MK, Slavin MA, Kontoyiannis DP (2018) Invasive fungal disease and cytomegalovirus infection: is there an association? Curr Opin Infect Dis 31(6):481\u2013489","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"5509_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bbmt.2013.10.003","volume":"20","author":"S Manjappa","year":"2014","unstructured":"Manjappa S et al (2014) Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant 20(1):46\u201352","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5509_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbmt.2003.08.011","volume":"10","author":"R Nakamura","year":"2004","unstructured":"Nakamura R et al (2004) Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant 10(1):49\u201357","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"5509_CR8","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","volume":"118","author":"AH Elmaagacli","year":"2011","unstructured":"Elmaagacli AH et al (2011) Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118(5):1402\u20131412","journal-title":"Blood"},{"issue":"3","key":"5509_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmii.2021.01.001","volume":"54","author":"CL Jerry Teng","year":"2021","unstructured":"Jerry Teng CL et al (2021) Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: a mini-review. J Microbiol Immunol Infect 54(3):341\u2013348","journal-title":"J Microbiol Immunol Infect"},{"issue":"2","key":"5509_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00277-014-2190-1","volume":"94","author":"JE Jang","year":"2015","unstructured":"Jang JE et al (2015) Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Ann Hematol 94(2):275\u2013282","journal-title":"Ann Hematol"},{"issue":"10","key":"5509_CR11","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/bmt.2013.49","volume":"48","author":"S Ito","year":"2013","unstructured":"Ito S et al (2013) CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant 48(10):1313\u20131316","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"5509_CR12","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00277-018-3585-1","volume":"98","author":"YL Zhang","year":"2019","unstructured":"Zhang YL et al (2019) Cytomegalovirus infection is associated with AML relapse after allo-HSCT: a meta-analysis of observational studies. Ann Hematol 98(4):1009\u20131020","journal-title":"Ann Hematol"},{"issue":"9","key":"5509_CR13","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/ajt.15515","volume":"19","author":"E Gimenez","year":"2019","unstructured":"Gimenez E et al (2019) Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): a systematic review, meta-analysis, and meta-regression analysis. Am J Transplant 19(9):2479\u20132494","journal-title":"Am J Transplant"},{"issue":"3","key":"5509_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.cmi.2021.10.008","volume":"28","author":"N Chuleerarux","year":"2022","unstructured":"Chuleerarux N et al (2022) The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Clin Microbiol Infect 28(3):332\u2013344","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"5509_CR15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.bbmt.2017.09.015","volume":"24","author":"J Beswick","year":"2018","unstructured":"Beswick J et al (2018) Incidence and risk factors for nontuberculous mycobacterial infection after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 24(2):366\u2013372","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5509_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/16078454.2022.2042064","volume":"27","author":"J Chen","year":"2022","unstructured":"Chen J et al (2022) Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes. Hematology 27(1):293\u2013299","journal-title":"Hematology"},{"issue":"3","key":"5509_CR17","doi-asserted-by":"publisher","first-page":"S388","DOI":"10.1016\/j.bbmt.2017.12.481","volume":"24","author":"C De Miguel","year":"2018","unstructured":"De Miguel C et al (2018) Clinical impact and burden of CMV infection on the use of resources in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 24(3):S388","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"5509_CR18","first-page":"569","volume":"90","author":"E Deconinck","year":"2005","unstructured":"Deconinck E et al (2005) Cytomegalovirus infection and chronic graft-versus-host disease are significant predictors of renal failure after allogeneic hematopoietic stem cell transplantation. Haematologica 90(4):569\u2013570","journal-title":"Haematologica"},{"issue":"7","key":"5509_CR19","doi-asserted-by":"publisher","first-page":"e13828","DOI":"10.1111\/petr.13828","volume":"24","author":"A Hama","year":"2020","unstructured":"Hama A et al (2020) Risk factors for secondary poor graft function after bone marrow transplantation in children with acquired aplastic anemia. Pediatr Transplant 24(7):e13828","journal-title":"Pediatr Transplant"},{"key":"5509_CR20","doi-asserted-by":"crossref","unstructured":"Lavall\u00e9e C et al (2017) Risk factors for the development of Clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: a single-center study in Qu\u00e9bec, Canada. Transplant Infect Dis Off J Transplant Soc 19(1)","DOI":"10.1111\/tid.12648"},{"key":"5509_CR21","doi-asserted-by":"crossref","unstructured":"Lin F et al (2022) The incidence, outcomes, and risk factors of secondary poor graft function in haploidentical hematopoietic stem cell transplantation for acquired aplastic anemia. Front Immunol 13","DOI":"10.3389\/fimmu.2022.896034"},{"issue":"23","key":"5509_CR22","doi-asserted-by":"publisher","first-page":"8497","DOI":"10.1002\/cam4.4353","volume":"10","author":"WR Lv","year":"2021","unstructured":"Lv WR et al (2021) Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: a single-center retrospective study. Cancer Med 10(23):8497\u20138506","journal-title":"Cancer Med"},{"key":"5509_CR23","doi-asserted-by":"crossref","unstructured":"Madsen K et al (2020) Incidence, outcomes and predictors of acute kidney injury post allogeneic stem cell transplant. Blood. 136((Madsen K.; Chen S.; Pasic I.) Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada): p. 16\u201317.","DOI":"10.1182\/blood-2020-136746"},{"key":"5509_CR24","unstructured":"Masouridi Levrat S et al (2016) Impact of different methods of T-cell depletion on poor graft function incidence after allogeneic hematopoietic stem cell transplantation. Bone marrow transplantation. 51((Masouridi Levrat S.; Simonetta F.; Tirefort Y.; Tsopra O.; Dantin C.; Beauverd Y.; Simon A.; Polchlopeck K.; Stephan C.; Chalandon Y.) Hematology, Geneva University Hospitals, Geneva, Switzerland): p. S429-S430."},{"issue":"6","key":"5509_CR25","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1080\/10428194.2021.1872072","volume":"62","author":"A Prabahran","year":"2021","unstructured":"Prabahran A et al (2021) Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation. Leuk Lymphoma 62(6):1482\u20131489","journal-title":"Leuk Lymphoma"},{"key":"5509_CR26","doi-asserted-by":"crossref","unstructured":"Prabahran AA et al (2021) Recurrent CMV viremia portends poor prognosis and results in significant resource utilization in patients with poor graft function post allogeneic stem cell transplantation. Blood 138((Prabahran A.A.; Chee L.C.Y.; Koldej R.M.; Ritchie D.) ACRF Translational Research Laboratory, The Royal Melbourne Hospital, Parkville, Australia): p. 4854.","DOI":"10.1182\/blood-2021-153912"},{"issue":"2","key":"5509_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.bbmt.2016.10.023","volume":"23","author":"H Sano","year":"2017","unstructured":"Sano H et al (2017) African American race is a newly identified risk factor for postengraftment blood stream infections in pediatric allogeneic blood and marrow transplantation. Biol Blood Marrow Transplant 23(2):357\u2013360","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"5509_CR28","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.bbmt.2019.11.005","volume":"26","author":"JL Saullo","year":"2020","unstructured":"Saullo JL et al (2020) Cytomegalovirus in allogeneic hematopoietic transplantation: impact on costs and clinical outcomes using a preemptive strategy. Biol Blood Marrow Transplant 26(3):568\u2013580","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5509_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/03007995.2019.1664826","volume":"36","author":"J Schelfhout","year":"2020","unstructured":"Schelfhout J et al (2020) Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant. Curr Med Res Opin 36(1):33\u201341","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"5509_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/tid.12264","volume":"16","author":"C Skert","year":"2014","unstructured":"Skert C et al (2014) A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation. Transpl Infect Dis 16(5):697\u2013712","journal-title":"Transpl Infect Dis"},{"key":"5509_CR31","doi-asserted-by":"crossref","unstructured":"Sun Y, Huang XJ (2019) Virus reactivation and low dose of CD34+ cell were associatied with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation. Bone marrow transplantation, 54((Sun Y.; Huang X.-J.) Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China): p. 265\u2013266.","DOI":"10.1007\/s00277-019-03715-w"},{"issue":"8","key":"5509_CR32","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00277-019-03715-w","volume":"98","author":"YQ Sun","year":"2019","unstructured":"Sun YQ et al (2019) Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation. Ann Hematol 98(8):1877\u20131883","journal-title":"Ann Hematol"},{"issue":"6","key":"5509_CR33","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s15010-022-01847-2","volume":"50","author":"D Teschner","year":"2022","unstructured":"Teschner D et al (2022) Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data. Infection 50(6):1543\u20131555","journal-title":"Infection"},{"issue":"11","key":"5509_CR34","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/tri.12831","volume":"29","author":"V Vinuesa","year":"2016","unstructured":"Vinuesa V et al (2016) Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting. Transplant Int Off J Eur Soc Organ Transplant 29(11):1196\u20131204","journal-title":"Transplant Int Off J Eur Soc Organ Transplant"},{"issue":"6","key":"5509_CR35","doi-asserted-by":"publisher","first-page":"652","DOI":"10.7150\/ijms.6337","volume":"11","author":"Y Xiao","year":"2014","unstructured":"Xiao Y et al (2014) Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation. Int J Med Sci 11(6):652\u2013657","journal-title":"Int J Med Sci"},{"issue":"1","key":"5509_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12185-018-2539-7","volume":"109","author":"Y Yamagishi","year":"2019","unstructured":"Yamagishi Y et al (2019) Risk factors and survival impact of readmission after single-unit cord blood transplantation for adults. Int J Hematol 109(1):115\u2013124","journal-title":"Int J Hematol"},{"issue":"12","key":"5509_CR37","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.bbmt.2014.08.010","volume":"20","author":"H Sousa","year":"2014","unstructured":"Sousa H et al (2014) Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review. Biol Blood Marrow Transplant 20(12):1958\u20131967","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"5509_CR38","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","volume":"21","author":"K Takenaka","year":"2015","unstructured":"Takenaka K et al (2015) Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant 21(11):2008\u20132016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 1","key":"5509_CR39","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/infdis\/jiz454","volume":"221","author":"G Haidar","year":"2020","unstructured":"Haidar G, Boeckh M, Singh N (2020) Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J Infect Dis 221(Suppl 1):S23-s31","journal-title":"J Infect Dis"},{"key":"5509_CR40","doi-asserted-by":"crossref","unstructured":"Eberhardt KA et al (2023) CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality. Bone Marrow Transplant","DOI":"10.1038\/s41409-023-01944-2"},{"issue":"3","key":"5509_CR41","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/blood-2016-04-713644","volume":"128","author":"AH Elmaagacli","year":"2016","unstructured":"Elmaagacli AH, Koldehoff M (2016) Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia. Blood 128(3):456\u2013459","journal-title":"Blood"},{"issue":"7","key":"5509_CR42","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","volume":"122","author":"ML Green","year":"2013","unstructured":"Green ML et al (2013) CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122(7):1316\u20131324","journal-title":"Blood"},{"issue":"5","key":"5509_CR43","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41375-022-01556-7","volume":"36","author":"G Maschmeyer","year":"2022","unstructured":"Maschmeyer G et al (2022) Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Leukemia 36(5):1215\u20131226","journal-title":"Leukemia"},{"issue":"12","key":"5509_CR44","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jtct.2021.09.010","volume":"27","author":"MK Yong","year":"2021","unstructured":"Yong MK et al (2021) American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. Transplant Cell Ther 27(12):957\u2013967","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"5509_CR45","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/imm.12991","volume":"155","author":"XH Luo","year":"2018","unstructured":"Luo XH et al (2018) The impact of inflationary cytomegalovirus-specific memory T cells on anti-tumour immune responses in patients with cancer. Immunology 155(3):294\u2013308","journal-title":"Immunology"},{"key":"5509_CR46","doi-asserted-by":"publisher","first-page":"1027593","DOI":"10.3389\/fimmu.2022.1027593","volume":"13","author":"XH Luo","year":"2022","unstructured":"Luo XH et al (2022) Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse. Front Immunol 13:1027593","journal-title":"Front Immunol"},{"issue":"3","key":"5509_CR47","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/cei\/uxac047","volume":"208","author":"ZY Fan","year":"2022","unstructured":"Fan ZY et al (2022) CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT. Clin Exp Immunol 208(3):332\u2013339","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"5509_CR48","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","volume":"16","author":"N Cantoni","year":"2010","unstructured":"Cantoni N et al (2010) Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 16(9):1309\u20131314","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"5509_CR49","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1631\/jzus.B1500005","volume":"16","author":"JM Shi","year":"2015","unstructured":"Shi JM et al (2015) Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years. J Zhejiang Univ Sci B 16(9):796\u2013804","journal-title":"J Zhejiang Univ Sci B"},{"issue":"1","key":"5509_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/tid.12328","volume":"17","author":"A Atalla","year":"2015","unstructured":"Atalla A et al (2015) Risk factors for invasive mold diseases in allogeneic hematopoietic cell transplant recipients. Transpl Infect Dis 17(1):7\u201313","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"5509_CR51","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.bbmt.2017.07.025","volume":"23","author":"MK Yong","year":"2017","unstructured":"Yong MK et al (2017) Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring. Biol Blood Marrow Transplant 23(11):1961\u20131967","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"5509_CR52","doi-asserted-by":"publisher","first-page":"e12852","DOI":"10.1111\/tid.12852","volume":"20","author":"B Pierce","year":"2018","unstructured":"Pierce B et al (2018) Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: a single-center study. Transpl Infect Dis 20(2):e12852","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"5509_CR53","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1159\/000523892","volume":"47","author":"BA Halouzkov\u00e1","year":"2022","unstructured":"Halouzkov\u00e1 BA et al (2022) Dosing of aminoglycosides in chronic kidney disease and end-stage renal disease patients treated with intermittent hemodialysis. Kidney Blood Press Res 47(7):448\u2013458","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"5509_CR54","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/08880010590935158","volume":"22","author":"A Zaucha-Prazmo","year":"2005","unstructured":"Zaucha-Prazmo A et al (2005) Cytomegalovirus (CMV) infections in children undergoing hematopoetic stem cell transplantation. Pediatr Hematol Oncol 22(4):271\u2013276","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"5509_CR55","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.seminhematol.2018.08.004","volume":"56","author":"Y Kong","year":"2019","unstructured":"Kong Y (2019) Poor graft function after allogeneic hematopoietic stem cell transplantation-an old complication with new insights(\u2606). Semin Hematol 56(3):215\u2013220","journal-title":"Semin Hematol"},{"issue":"11","key":"5509_CR56","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/cid\/cix690","volume":"65","author":"C Girmenia","year":"2017","unstructured":"Girmenia C et al (2017) Incidence, risk factors and outcome of pre-engraftment gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: an Italian prospective multicenter survey. Clin Infect Dis 65(11):1884\u20131896","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5509_CR57","first-page":"40","volume":"45","author":"L \u00d6ks\u00fcz","year":"2022","unstructured":"\u00d6ks\u00fcz L et al (2022) The association of CMV infection with bacterial and fungal infections in hematopoietic stem cell transplant recipients: a retrospective single-center study. New Microbiol 45(1):40\u201350","journal-title":"New Microbiol"},{"issue":"1","key":"5509_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jmii.2016.02.003","volume":"51","author":"CH Wang","year":"2018","unstructured":"Wang CH et al (2018) Characteristics comparisons of bacteremia in allogeneic and autologous hematopoietic stem cell-transplant recipients with levofloxacin prophylaxis and influence on resistant bacteria emergence. J Microbiol Immunol Infect 51(1):123\u2013131","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"5509_CR59","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cmi.2022.07.001","volume":"29","author":"F Khawaja","year":"2023","unstructured":"Khawaja F et al (2023) Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium. Clin Microbiol Infect 29(1):44\u201350","journal-title":"Clin Microbiol Infect"},{"issue":"25","key":"5509_CR60","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM et al (2017) Letermovir Prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 377(25):2433\u20132444","journal-title":"N Engl J Med"},{"issue":"6","key":"5509_CR61","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1111\/ajt.15764","volume":"20","author":"FM Marty","year":"2020","unstructured":"Marty FM et al (2020) Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant 20(6):1703\u20131711","journal-title":"Am J Transplant"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05509-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05509-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05509-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T17:05:15Z","timestamp":1708189515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05509-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["5509"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05509-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"23 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Although Jie Liu and Yi Sun were employees of MSD China, all of the authors declare there are no conflicts of interest related to the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}